## **OPTIMA HEALTH PLAN**

## PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST\*

<u>Directions</u>: <u>The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request</u>. All other information may be filled in by office staff; fax to <u>1-800-750-9692</u>. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. <u>If information provided is not complete, correct, or legible, authorization may be delayed.</u>

<u>Drug Requested</u>: **Vyleesi**<sup>™</sup> (bremelanotide acetate)

MEMBER & PRESCRIBER INF	<b>TORMATION:</b> Authorization may be delayed if incomplete.
Member Name:	
Member Optima #:	
Prescriber Name:	
	Date:
Office Contact Name:	
Phone Number:	Fax Number:
DEA OR NPI #:	
DRUG INFORMATION: Authoriz	zation may be delayed if incomplete.
Drug Form/Strength:	
Dosing Schedule:	Length of Therapy:
Diagnosis:	ICD Code:
Weight:	Date:
Quantity Limit: 8 doses (2.4 mL) p	
	all that apply. All criteria must be met for approval. To support luding lab results, diagnostics, and/or chart notes, must be provided
Authorization Criteria:	
☐ Member is pre-menopausal	
☐ Member is 18 years of age or older	
	ctive Sexual Desire Disorder (HSDD) with symptoms (e.g., low sexual printerpersonal difficulty) that have persisted for at least 6 months
<ul> <li>Member's HSDD is <u>NOT</u> related to relationship issue</li> </ul>	o any other medical or psychiatric condition, substance abuse or

(Continued on next page)

PA Vylessi (CORE) (Continued from previous page)

Member has had an unsuccessful 8-week trial of Addyi <sup>®</sup> (*requires prior authorization: See <a href="https://www.optimahealth.com">www.optimahealth.com</a> for prior authorization form; chart notes must be submitted to document Addyi <sup>®</sup> failure)
The prescribing physician has determined the average pre-treatment number of satisfying sexual events for the patient over a specific time frame (example: two satisfying sexual events over 1 month) in order to evaluate Vyleesi treatment efficacy after therapy initiation
Member does <b>NOT</b> have uncontrolled hypertension or known cardiovascular disease
Member will $\underline{\mathbf{NOT}}$ be using more than 8 doses per month or more than one dose within a 24-hour time-frame

Not all drugs may be covered under every Plan.

If a drug is non-formulary on a Plan, documentation of medical necessity will be required.

\*\*Use of samples to initiate therapy does not meet step edit/ preauthorization criteria. \*\*

\*Previous therapies will be verified through pharmacy paid claims or submitted chart notes. \*